309 related articles for article (PubMed ID: 22445709)
41. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
42. Cinacalcet improves endothelial dysfunction and cardiac hypertrophy in patients on hemodialysis with secondary hyperparathyroidism.
Choi SR; Lim JH; Kim MY; Hong YA; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Nephron Clin Pract; 2012; 122(1-2):1-8. PubMed ID: 23466553
[TBL] [Abstract][Full Text] [Related]
43. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
44. Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Schumock GT; Walton SM; Lee TA; Marx SE; Audhya P; Andress DL
Nephron Clin Pract; 2011; 117(2):c151-9. PubMed ID: 20699620
[TBL] [Abstract][Full Text] [Related]
45. Association of cinacalcet adherence and costs in patients on dialysis.
Lee A; Song X; Khan I; Belozeroff V; Goodman W; Fulcher N; Diakun D
J Med Econ; 2011; 14(6):798-804. PubMed ID: 21988567
[TBL] [Abstract][Full Text] [Related]
46. [Kidney and bone update : the 5-year history and future of CKD-MBD. Parathyroidectomy for secondary hyperparathyroidism].
Tominaga Y
Clin Calcium; 2012 Jul; 22(7):1083-8. PubMed ID: 22750941
[TBL] [Abstract][Full Text] [Related]
47. Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
Ichii M; Ishimura E; Okuno S; Chou H; Kato Y; Tsuboniwa N; Nagasue K; Maekawa K; Yamakawa T; Inaba M; Nishizawa Y
Nephron Clin Pract; 2010; 115(3):c195-202. PubMed ID: 20413997
[TBL] [Abstract][Full Text] [Related]
48. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
49. Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice.
Bover J; Perez R; Molina M; Benavides B; Ariza F; Miguel JL; Tornero F; Torregrosa JV;
Nephron Clin Pract; 2011; 118(2):c109-21. PubMed ID: 21150219
[TBL] [Abstract][Full Text] [Related]
50. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
Am J Nephrol; 2013; 37(5):405-12. PubMed ID: 23594726
[TBL] [Abstract][Full Text] [Related]
51. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
[TBL] [Abstract][Full Text] [Related]
52. Parathyroid gland ultrasound patterns and biochemical findings after one-year cinacalcet treatment for advanced secondary hyperparathyroidism.
Vulpio C; Bossola M; De Gaetano A; Maresca G; Di Stasio E; Zagaria L; Luciani G; Giordano A; Castagneto M
Ther Apher Dial; 2010 Apr; 14(2):178-85. PubMed ID: 20438540
[TBL] [Abstract][Full Text] [Related]
53. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
[TBL] [Abstract][Full Text] [Related]
54. Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?
Kakuta T; Tanaka R; Kanai G; Sawaya A; Hirukawa T; Sato A; Saito A
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S20-7. PubMed ID: 19765255
[TBL] [Abstract][Full Text] [Related]
55. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Rose M; Shepherd J; Harris P; Pickett K; Lord J
Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
[TBL] [Abstract][Full Text] [Related]
56. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
57. Cost-utility analysis of cinacalcet in addition to standard of care in the UK.
Ray JA; Valentine WJ; Palmer AJ
Nephrol Dial Transplant; 2007 Nov; 22(11):3355-7; author reply 3357-8. PubMed ID: 17785347
[No Abstract] [Full Text] [Related]
58. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
[TBL] [Abstract][Full Text] [Related]
59. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
60. Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis.
McManus C; Oh A; Lee JA; Hur C; Kuo JH
Surgery; 2021 Jan; 169(1):94-101. PubMed ID: 32732069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
